News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
UK Trade Group Suspends Merck & Co., Inc. Over Drug Promotion
October 2, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, Oct 2 (Reuters) - Britain's pharmaceutical trade body has suspended the local operation of U.S. drugmaker Merck & Co Inc for a minimum of three months for unacceptable promotional practices.
>>>
Discuss This Story
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Regulatory
Europe
Merck & Co.
MORE ON THIS TOPIC
Huntington’s disease
Roche scraps 2 Huntington’s studies, handing Ionis more bad news
July 10, 2026
·
2 min read
·
Tristan Manalac
Artificial intelligence
Biopharma R&D needs ‘structural redesign’ to maximize AI impact: report
July 9, 2026
·
2 min read
·
Nick Paul Taylor
FDA
Cancer, rare disease dominate FDA approvals in H1 2026 as AstraZeneca, J&J clean up
July 9, 2026
·
1 min read
·
Heather McKenzie
Cardiovascular disease
AstraZeneca, Ionis slip as ATTR-CM drug fails Phase 3
July 9, 2026
·
3 min read
·
Tristan Manalac
